VYNE Therapeutics Inc.
VYNE
$0.59
$0.000.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -23.08% | 144.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -23.08% | 144.93% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -23.08% | 144.93% | |||
| SG&A Expenses | -12.31% | -0.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.81% | 4.60% | |||
| Operating Income | 33.02% | -3.31% | |||
| Income Before Tax | 33.26% | -29.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.21% | -29.22% | |||
| Earnings from Discontinued Operations | -15.75% | 1,925.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.56% | -26.50% | |||
| EBIT | 33.02% | -3.31% | |||
| EBITDA | 33.03% | -3.32% | |||
| EPS Basic | 33.63% | -26.37% | |||
| Normalized Basic EPS | 33.30% | -5.24% | |||
| EPS Diluted | 33.63% | -26.37% | |||
| Normalized Diluted EPS | 33.30% | -5.24% | |||
| Average Basic Shares Outstanding | 0.08% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||